Unlike chemotherapy, which can cause damage to healthy cells leading to adverse side effects, gefitinib specifically targets and inhibits the EGFR pathway that is often overexpressed in cancer cells, making it a more targeted therapy with potentially fewer side effects. This evidence concerns the gene EGFR and cancer.